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Abstract
Previous studies have indicated that Epstein-Barr virus (EBV) can modulate the Wnt pathway in virus-infected cells and this
effect is mediated by EBV-encoded oncogene latent membrane protein 1 (LMP1). Here we have reassessed the role of LMP1
in regulating the expression of various mediators of the canonical Wnt cascade. Contradicting the previous finding, we
found that the levels of E-cadherin, b-catenin, Glycogen Synthase Kinase 3ß (GSK3b), axin and a-catenin were not affected
by the expression of LMP1 sequences from normal B cells or nasopharyngeal carcinoma. Moreover, we also show that LMP1
expression had no detectable effect on the E-cadherin and b-catenin interaction and did not induce transcriptional
activation of b-catenin. Taken together these studies demonstrate that EBV-mediated activation of Wnt pathway is not
dependent on the expression of LMP1.
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Introduction
The oncogenic potential of Epstein-Barr virus (EBV) is well
recognized, and the virus is associated with a number of human
malignancies, including Burkitt’s lymphoma (BL) and nasopha-
ryngeal carcinoma (NPC) [1]. Each of the EBV-associated
malignancies is characterised by a unique viral and cellular
phenotype. In most of the EBV-associated malignancies the viral
gene expression is often restricted to a limited number of proteins.
This limited gene expression is often considered as one of the most
important factors in the pathogenesis and escape of these
malignancies from immune control (see reviews [2,3]. EBV-
encoded oncogene latent membrane protein 1 (LMP1), has been
recognised as one of most crucial latent proteins for EBV-
mediated transformation of normal B cells and is uniquely able to
induce malignant outgrowth and hyperplasia in transgenic mice
[4]. Furthermore, LMP1 is also known to exhibit pleiotropic
effects on the cellular phenotype of B cells which include induction
of activation antigens, the expression of inhibitors of programmed
cell death and NF-kB activation through the TRAF signalling
pathway [5–7]. Previous studies have shown that LMP1 acts as a
constitutively active receptor like molecule independent of the
binding of a ligand [1,8]. The transmembrane domains mediate
oligomerization of LMP1 molecules in the plasma membrane, a
prerequisite for LMP1 function [1,9].
Over the last few years, there has been increasing evidence to
suggest EBV is capable of modulating the Wnt pathway [10–13].
In particular, it has been suggested LMP1 expression can repress
the expression of E-cadherin [14–16]. The current experiments
reported here were undertaken to reassess the role of LMP1 in
regulating the expression of E-cadherin and to further explore the
mechanism by which LMP1 modulates the function of various
mediators of the canonical Wnt cascade. Here we show that
transient or stable expression of LMP1 sequences from normal B
cells and NPC does not impair the expression of E-Cadherin and
other mediators of the Wnt pathway. Furthermore, we also
demonstrate that LMP1 expression in human cells had minimal
effect on the interaction of E-cadherin and b-catenin thus no
evidence of b-catenin-mediated transcriptional activation was
observed.
Results and Discussion
Expression of Wnt pathway mediators in LMP1-positive
cells
To explore the effect of LMP1 on other mediators of the Wnt
pathway, we transiently transfected HaCaT and MDCK cells with
expression vectors encoding LMP1-GFP or the control EGFP
vector. These LMP1 sequences were either derived from the
prototype B95.8 isolate, spontaneous LCLs (HS6, QC and PM) or
NPC (NPC9 and CAO). After transfection, these cells were
examined using confocal microscopy for the expression of E-
cadherin, b-catenin or actin. Representative data from a series of
experiments is presented in Figure 1 (panel A). In contrast to the
previous studies, we observed very little difference in the
expression of E-cadherin or b-catenin in LMP1 or EGFP-positive
cells. Both HaCaT and MDCK cells showed minimal effect of
LMP1 on the expression of E-cadherin, b-catenin. Interestingly,
LMP1 sequences from both normal B cells or from NPC showed
no effect on the expression of E-cadherin and b-catenin. On the
PLoS ONE | www.plosone.org 1 September 2008 | Volume 3 | Issue 9 | e3254Figure 1. Panel A: Effect of LMP1 on the expression of E-cadherin, b-catenin and actin. HaCaT or MDCK cells were transiently transfected
with expression vectors encoding LMP1 protein fused to EGFP. LMP1 sequences were derived from either the prototype B95.8 isolate, spontaneous
LCLs (HS6, QC and PM) or NPC biopsies (CAO and NPC9). Following transfection, these cells were cultured for 36–48 h and then assessed for the
expression of E-cadherin, b-catenin and actin using confocal microscopy. HaCaT cells transfected with pcDNA3.1 vector with or without B95.8-LMP1
were also assessed for b-catenin expression (bottom panels). Panel B: HEK293 cells transfected with various LMP1 sequences were also processed for
SDS-PAGE and immunoblot analysis. Antibodies specific for b-catenin, E-cadherin, a-catenin, GSK3b were used to assess the level of expression each
of these components in LMP1 or EGFP expressing cells. In addition, the level of LMP1 and GAPDH expression was also assessed in these cells.
Representative data from one of the five different experiments is presented in this figure.
doi:10.1371/journal.pone.0003254.g001
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filaments in LMP1 expressing cells which is consistent with the
previous studies published by Dawson and colleagues who also
showed actin filament remodelling following LMP1 expression in
3T3 fibroblasts [17]. To ensure that the results described above
were not influenced by the covalent linking of LMP1 with EGFP,
we also expressed LMP1 protein in HaCaT cells without EGFP
and then assessed the expression of b-catenin. Consistent with the
data presented above, we observed no significant difference in the
pattern of b-catenin expression in HaCaT cells transfected with
either pcDNA3.1 (control) or pcDNA3.1 encoding B95.8-LMP1
(Fig. 1, Panel A).
To further confirm these observations, we resolved the protein
samples (normalised for GFP expression using FACS analysis)
from these transfected cells on SDS-PAGE followed by immuno-
blotting. Data presented in Figure 1, panel B clearly demonstrate
that the levels of E-cadherin and b-catenin were largely unaffected
by the expression of LMP1. In addition, expression levels of other
Wnt pathway mediators and potential modulators (a-catenin and
GSK3b) was indistinguishable between LMP1 and EGFP-positive
cells. It is important to point out that the lack of any modulation of
Wnt pathway mediators by LMP1 in these experiments was not
due to either low levels of LMP1 expression or the loss of LMP1-
mediated signalling due to covalent linking of EGFP. All LMP1
expression vectors showed normal to high levels of LMP1
expression which was quite comparable to the levels seen in
EBV-infected B cells. Furthermore, data presented in figure 2
clearly shows that expression vectors encoding LMP1 protein
fused to GFP at the C-terminus are fully capable of activating NF-
kB and STAT3 which is comparable to that seen with LMP1
protein without GFP [18]. It is interesting to note that LMP1
sequences displayed some differences with respect to their ability
to activate NF-kB and STAT3, although this variation not
particularly associated with any specific disease setting from which
the LMP1 sequence was isolated.
To ensure that these observations were not influenced by the
transient expression of LMP1, we established stable transfectants
of the HaCaT cell line expressing B95.8-LMP1 and EGFP. These
cells were processed for E-cadherin, b-catenin and actin expression
using confocal microscopy. Similar to data obtained with transient
transfection, HaCaT cells stably expressing LMP1 showed
minimal change in the expression of E-cadherin and b-catenin
when compared to the cells expressing EGFP alone (Figure 3,
panel A). Immunoblot analysis of protein samples from these cells
also showed comparable levels of E-cadherin, b-catenin a-catenin,
GSK3b, and axin in LMP1 and EGFP expressing cells (Figure 3,
Panel B). Furthermore, analysis of b-catenin expression in the
cytoplasmic and nuclear fraction of cells expressing LMP1 or
EGFP revealed no significant difference (data not shown). Taken
together, these data clearly demonstrate that LMP1 does not
Figure 2. Effects of the LMP1 expression constructs on the activation of cellular signaling pathways. NFkB (panel A) and STAT (panel B)
activation induced by B95-8-LMP1, HS6-LMP1, NPC9-LMP1, QC-LMP1 or CAO-LMP1 was assessed by quantitation of the luciferase produced from a
co-transfected reporter plasmids, 3Enh.kB-ConALuc or GRR(5)-Luc. The data were normalized for transfection efficiency by measuring GFP-positive
cells and then expressed relative to the activity obtained with the B95-8-LMP1 (100%) without subtracting the basal activity in control pEGFP-N1-
transfected cells. Results are the mean and standard deviation of at least four separate experiments.
doi:10.1371/journal.pone.0003254.g002
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modulators of the Wnt cascade and there is no evidence of
accumulation of b-catenin either in the cytoplasm or nucleus
following expression of LMP1.
Effect of LMP1 on the interaction of E-Cadherin, b-
catenin and a-catenin with the surface membrane
Although the data presented above clearly indicated that LMP1
does not influence the expression of individual components of the
Wnt pathway, it is possible that LMP1 may disrupt the interaction
of E-cadherin and b-catenin. A series of experiments were
designed to immunoprecipitate E-cadherin and b-catenin com-
plexes from LMP1 and EGFP expressing cells. In the first set of
experiments, E-Cadherin was immunoprecipitated from the whole
cell extract and then resolved on SDS-PAGE followed by
immunoblotting. The immunoblots were probed with anti-E-
cadherin, anti-b-catenin and anti- a-catenin antibodies. Data
presented in Figure 4, panel A shows that LMP1 expression in
HaCaT cells had very little effect on the interaction of E-cadherin,
b-catenin and a-catenin. To further confirm these observations,
we surface labelled LMP1 and EGFP-positive HaCaT cells with
NHS-biotin and immunoprecipitated the biotin-labelled proteins
with either anti-E-cadherin or anti-b-catenin antibodies. These
immunoprecipitates were resolved on SDS-PAGE followed by
immunoblotting with streptavidin, anti-E-cadherin or anti-b-
catenin antibodies. Similar to the data presented in the panel A,
we noticed very little effect of LMP1 expression on the interaction
of E-Cadherin and b-catenin on the cell surface (Fig. 4, panel B).
Previous studies have suggested that EBV-mediated activation
of b-catenin involves stabilization of this protein which leads to b-
catenin-mediated increased transcriptional activity. To explore the
possibility that this effect may be mediated by LMP1, stable
transfectants (LMP1 and EGFP-positive) were pretreated with
cycloheximide to block fresh protein synthesis and protein samples
collected at different time intervals. These samples were then
resolved on SDS-PAGE followed by immunoblotting with the b-
catenin-specific antibody. Data presented in Figure 5, panel A,
shows no evidence of increased stabilization of b-catenin in LMP1
expressing cells. These experiments were repeated at least five
times and we were unable to see any firm evidence of LMP1-
medaited stabilization of b-catenin.
Another possible approach to test the stabilization of b-catenin
is to assess downstream transcriptional activity mediated by this
protein. It is now well established that stabilized b-catenin forms a
complex with Tcf/lymphoid enhancer factor transcriptional
factors and that this complex transactivates various cellular
oncogenes (e.g. c-myc and cyclin D1) which play crucial role in
cell transformation and tumour development [19,20]. To
Figure 3. Effect of stable LMP1 expression on the canonical Wnt pathway mediators. HaCaT cells were transfected with expression vectors
encoding LMP1 protein from the prototype B95.8 isolate. Following transfection these cells were cultured in growth medium supplemented with
Geneticin for 3 weeks and stable transfectants isolated by FACSort. These stable transfectants were assessed for the expression of E-cadherin, b-
catenin and actin using confocal microscopy (Panel A) and as well for a-catenin, GSK3b and Axin by SDS-PAGE and immunoblotting.
doi:10.1371/journal.pone.0003254.g003
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mediated transcriptional activation of Tcf, we transfected HaCaT
cells with EGFP or LMP1-GFP expression plasmids (B95.8, CAO,
HS6, NPC9 or QC) in combination with Tcf reporter plasmids
containing three copies of WT Tcf-binding site (TOPFLASH) and
three copies of mutated site as a negative control (FOPFLASH)
and used these cells in luciferase reporter assays. Representative
data one of these experiments is presented in Figure 5, Panel B.
Consistent with data presented in panel A, we observed no
evidence of b-catenin-mediated transcriptional activity in LMP1-
expressing cells.
These experiments were undertaken to reassess the role of
LMP1 in modulating the canonical Wnt pathway. We have used
human epithelial and keratinocyte cell lines to express different
sequence variants of LMP1 and studied its effect on the regulation
of E-cadherin and b-catenin interaction/function. The effect of
LMP1 expression was assessed using both a transient and stable
expression system. Confocal microscopic studies showed none of
the LMP1 sequences (derived form either normal B cells or NPC)
had any dramatic effect on the expression of E-Cadherin and b-
catenin. Furthermore, we also found no effect of LMP1 on the
interaction of E-Cadherin and b-catenin and the downstream b-
catenin-mediated transcriptional activity. Based on this extensive
and in depth analysis, we propose that it is unlikely that LMP1
plays any significant role in the modulation of the Wnt pathway. It
is very difficult to precisely identify the reason for difference in the
results described here and those described previously by other
groups [14–16]. One possible reason might be that different cell
lines respond differentially to LMP1 signalling. For example our
studies were primarily based on human epithelial cell line HaCaT,
while other groups have used canine epithelial cell line (MDCK).
Furthermore, it is also possible that minor differences within the
LMP1 sequences used by different groups may differentially
impact on the expression of E-Cadherin and other mediators of
Wnt pathway.
It is important to stress here that our studies do not refute a
potential role of EBV in activating b-catenin and its transcriptional
activity. It is possible that another EBV protein(s) play a crucial
role in regulating b-catenin activity in virus-infected normal and
malignant cells. Indeed, recent studies by Morrison and colleagues
have shown that EBV-encoded Latent membrane protein 2A
(LMP2A) activates b-catenin in epithelial cells through the PI3/
AKt pathway [12,21]. In this context, it is important to point out
that LMP2A is consistently expressed in type II malignancies such
as NPC where dysregulation of E-cadherin or b-catenin expression
has been reported [21–23].
Materials and Methods
Expression Plasmids and Transfection
LMP1 sequences were amplified from prototype B95.8 isolate
(referred to as B95.8-LMP1), NPC (referred to as NPC9-LMP1,
CAO-LMP1) or spontaneous lymphoblastoid cell lines (LCL;
HS6-LMP1, QC-LMP1, PM-LMP1) using sequence-specific
primers and PCR and cloned in frame into the pEGFP-N1 vector
(Clontech, Palo Alto, California). Amplified LMP1 sequences were
Figure 4. Effect of LMP1 expression on the interaction of E-cadherin and b-catenin. Two different methods were used to assess the effect
of LMP1 on this interaction. Firstly, E-cadherin was immunoprecipated from the cells stably expressing either LMP1 or EGFP. These
immunoprecipitates were then resolved on SDS-PAGE gel followed by immunoblotting (Panel A). These immunoblots were probed with antibodies
specific for E-cadherin, b-catenin and a-catenin. In the second strategy, live HaCaT cells stably expressing either LMP1 or EGFP were initially surface
labelled with biotin and then immunoprecipitated with anti- E-cadherin or anti-b-catenin antibodies. These immunoprecipitates were then resolved
on SDS-PAGE gel followed by immunoblotting (Panel A). These immunoblots were probed with either streptavidin or antibodies specific for E-
cadherin and b-catenin.
doi:10.1371/journal.pone.0003254.g004
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as to express a fusion protein with the Green Fluorescent Protein
(GFP) at the C-terminus. Human epithelial or keratinocyte cell
lines (HaCaT, HEK293, SVMR6) or Madin-Darby canine kidney
cell line (MDCK; ATCC no. CCL-34) were transfected with
either pEGFP-N1 or LMP1-GFP expression vectors using
lipofectamine 2000 (Invitrogen, Calsbad, California). In some
experiments, an expression vector (pcDNA3.1) encoding full-
Figure 5. Panel A: Effect of LMP1 on the half-life of b-catenin. HaCaT cells expressing LMP1-GFP or EGFP pre-treated with cyclohexamide and
then equal aliquots of cells were removed at time points 0 min, 45 min, 90 min, 135 min and 180 min; and lysed in RIPA buffer, resolved on SDS-
polyacrylamide gel followed by immunoblotting with antibodies specific b-catenin. Protein bands densitometricaly analysed using Imagequant
software. Panel B: Assessment of b-catenin transcriptional activity in LMP1 expressing cells. LMP1 or EGFP expressing cells (HaCaT, Hek293 or SW480)
were co-transfected with TOPFlash or FOPFlash plasmids. These cells were used in luciferase reporter assays as described in the ‘‘Material and
Methods’’ section. The TOPFlash luciferase activity produced by each sample is shown relative to the matching FOPFlash activity produced.
doi:10.1371/journal.pone.0003254.g005
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were cultured for 36–48 h in RPMI-1640 supplemented with 10%
FCS (growth medium) and the transfection efficiency was assessed
by the expression of EGFP using FACScalibur (Becton Dickinson,
San Diego, California). In some cases transfected cells were
cultured in growth medium supplemented with Geneticin
(Invitrogen, Calsbad, California, 500 mg/ml) for 3 weeks and
stable transfectants isolated by FACSort (Mo-Flo Fluoroscence
Activated Cell Sorter, Dako Cytomation, Forte Collins, CO).
Immunofluorescence
For immunofluorescence studies, LMP1 or EGFP expressing cells
were seeded onto coverslips and cultured overnight in growth
medium. After incubation, these cells were washed in PBS plus
Calcium and Magnesium (PBSCM) and then fixed in 3%
paraformaldehyde and permeabilised with 0.1% Saponin (Sigma
Aldrich, St Louis, MO) in 5% FCS/PBSCM. After fixation, cells
were incubated with monoclonal or polyclonal antibodies specific for
LMP1 (Dako, Carpinteria, CA), b-Catenin (BD Transduction
Laboratories, San Jose, CA) and E-Cadherin (BD Transduction
L a b o r a t o r i e s ,S a nJ o s e ,C A ) ,a n dT R I T Cc o n j u g a t e da n t i - P h a l l o i d i n
antibody (Sigma Aldrich, St Louis, MO) in 5% FCS/PBSCM and
incubated on the cells for 1 hour at room temperature. After washing
in 0.1% Saponin/PBSCM,cells were incubated with anti-mouseCy3
(JacksonImmunoResearchLaboratories,BaltimorePike,PA).Finally
the cells were washed and examined by confocal microscopy (Leica
TCS SP2; Leica, Mannheim, Germany).
Surface Labeling, Immunoprecipitation and
Immunoblotting
Monolayers of HaCaT cells stably expressing LMP1 or EGFP
were washed with cold PBS (pH 8.0) and labelled with 2 mM EZ-
Link Sulfo-NHS-Biotin Reagent (Pierce, Rockford, IL). The
reaction was quenched with PBS and 100 mM Glycine prior to
solubilisation with modified radioimmunoprecipitation (RIPA)
buffer (Upstate Inc. Waltham, MA). These cell extracts were
initially incubated with E-Cadherin-specific antibody for 2.5 hours
followed by an overnight incubation with Protein G Sepharose
beads (Roche Diagnostics, Mannheim, Germany). After incuba-
tion, beads were extensively washed with RIPA buffer and protein
samples resolved using standard SDS-PAGE, transferred to
nitrocellulose membrane and incubated with HRP-conjugated
streptavidin (Chemicon, Temecula, CA), and antibodies specific
for E-Cadherin, b-catenin or a-catenin (BD transduction labora-
tories, San Jose, CA),. Protein bands were detected using
Chemiluminescence Reagent Plus (PerkinElmer, Life Sciences,
Boston, MA) and their intensity compared by densitometric
analysis using Imagequant software (Molecular Dynamics, Sunny-
vale, CA). In some experiments protein samples from EGFP and
LMP1-GFP expressing cells were directly resolved on the SDS-
PAGE, transferred to nitrocellulose membrane and incubated with
HRP-conjugated streptavidin, and antibodies specific for LMP1,
E-Cadherin, b-catenin, a-catenin or GSK3b (Becton Dickson
Transduction Laboratories, San Jose, CA), GAPDH (Ambion,
Austin, TX) and Axin (Zymed Laboratories Inc. San Francisco,
CA).
Intracellular stability analysis of b-catenin
The human keratinocyte cell line HaCaT was transiently
transfected with expression constructs encoding LMP1-GFP or
EGFP as described above. At 30 h posttransfection, cyclohex-
amide (50 mg/ml) was added to 1610
6 cells and equal aliquots of
cells were removed at time points 0 min, 45 min, 90 min, 135 min
and 180 min; and lysed in RIPA buffer, resolved on SDS-
polyacrylamide gel, transferred to nitrocellulose membrane and
incubated with antibodies specific b-catenin. Protein bands were
detected using Chemiluminescence Reagent Plus densitometricaly
analysis using Imagequant software.
Analysis of b-catenin transcription activity
Approximately, 10
6 HaCaT cells were co-transfected with
TOPFlash or FOPFlash (Upstate Biotechnology, Lake Placid,
NY). in combination with EGFP or LMP1-GFP expression
plasmids (B95.8, CAO, HS6, NPC9 or QC) at a ratio of 1:2.
After incubation for 24 h, a small aliquot of these cells was
analysed for GFP expression by FACSCalibur and cell numbers
were accordingly standardised based on GFP positive cells. These
cells were used in luciferase reporter assays according to the
manufacturer’s instructions (Promega, Madison, WI). The TOP-
Flash luciferase activity produced by each sample is shown relative
to the matching FOPFlash activity produced.
Gene transfection and luciferase reporter assay
HaCaT cells were grown to late-log phase of cell growth prior to
co-transfection. On the day of transfection, luciferase reporter
plasmids for either NF-kB (3.Enh-Luc) or STAT (pGRR5-Luc)
(Fielding et al., 2001) were combined with LMP1-GFP expression
plasmids (B95–8, CAO, HS6, NPC9 or QC) and pEGFP-N1
expression vector in a 1:2 ratio. Electroporation was used for the
STAT co-transfections where 9 mg of total DNA was used for
5610
6 cells, and 0.8 mg total DNA was added to 2610
5 cells when
using Effectene
TM (Qiagen) for the NF-kB co-transfections. After
growth for 24 hours in RPMI medium supplemented with
antibiotics and 10% FCS, cells were harvested and resuspended
in PBS supplemented with 2% FCS. To measure successful
transfection a small aliquot was taken for FACScan (Becton
Dickson) analysis of GFP expression, and the volume remaining
was subsequently standardized to the sample of lowest efficiency.
The transfection efficiencies were generally between 40–50%. To
report the transcription factor activity, the cells were pelleted and
lysed with 120 ml of Cell Culture Lysis Reagent (Promega) and the
luciferase activity measured on 20 ml triplicates by addition of
Luciferase Assay Reagent (Promega). The luciferase activity
produced by each sample was calculated relative to the activity
produced by the prototype B95-8-LMP1.
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